AP2710A - Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors - Google Patents

Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors

Info

Publication number
AP2710A
AP2710A AP2009004790A AP2009004790A AP2710A AP 2710 A AP2710 A AP 2710A AP 2009004790 A AP2009004790 A AP 2009004790A AP 2009004790 A AP2009004790 A AP 2009004790A AP 2710 A AP2710 A AP 2710A
Authority
AP
ARIPO
Prior art keywords
pyrido
inhibitors
pyrimidinone compounds
pyrimidinone
compounds
Prior art date
Application number
AP2009004790A
Other languages
English (en)
Other versions
AP2009004790A0 (en
Inventor
Dilip Bhumralkar
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2009004790A0 publication Critical patent/AP2009004790A0/xx
Application granted granted Critical
Publication of AP2710A publication Critical patent/AP2710A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
AP2009004790A 2006-09-15 2007-09-03 Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors AP2710A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30
PCT/IB2007/002578 WO2008032162A1 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (2)

Publication Number Publication Date
AP2009004790A0 AP2009004790A0 (en) 2009-04-30
AP2710A true AP2710A (en) 2013-07-30

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009004790A AP2710A (en) 2006-09-15 2007-09-03 Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors

Country Status (41)

Country Link
US (3) US7696213B2 (2)
EP (1) EP2074122B9 (2)
JP (1) JP4718637B2 (2)
KR (1) KR101099926B1 (2)
CN (1) CN101573358B (2)
AP (1) AP2710A (2)
AR (1) AR062785A1 (2)
AT (1) ATE514695T1 (2)
AU (1) AU2007297212B8 (2)
BR (1) BRPI0716749B8 (2)
CA (1) CA2663401C (2)
CL (1) CL2007002682A1 (2)
CR (1) CR10662A (2)
CU (1) CU23783B7 (2)
CY (1) CY1111911T1 (2)
DK (1) DK2074122T5 (2)
DO (1) DOP2009000039A (2)
EA (1) EA016388B1 (2)
ES (1) ES2366489T3 (2)
GE (1) GEP20115306B (2)
GT (1) GT200700077A (2)
HN (1) HN2007000267A (2)
HR (1) HRP20110621T2 (2)
IL (1) IL197243A (2)
MA (1) MA30709B1 (2)
ME (1) MEP8009A (2)
MX (1) MX2009002927A (2)
MY (1) MY146420A (2)
NI (1) NI200900032A (2)
NO (1) NO342357B1 (2)
NZ (1) NZ575167A (2)
PE (1) PE20080670A1 (2)
PL (1) PL2074122T3 (2)
PT (1) PT2074122E (2)
RS (2) RS51927B (2)
SI (1) SI2074122T1 (2)
TN (1) TN2009000085A1 (2)
TW (1) TWI334353B (2)
UY (1) UY30588A1 (2)
WO (1) WO2008032162A1 (2)
ZA (1) ZA200901477B (2)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115306B (2) * 2006-09-15 2011-10-10 Pfizer Prod Inc
PL2139484T3 (pl) * 2007-04-10 2013-12-31 Exelixis Inc Sposoby leczenia raka z zastosowaniem pirydopirymidynonów jako inhibitorów PI3K alfa
KR20090130104A (ko) * 2007-04-11 2009-12-17 엑셀리시스, 인코포레이티드 암 치료를 위한 pi3k-알파의 억제제로서의 피리도〔2,3­d〕피리미딘­7­온 화합물
KR20110028651A (ko) * 2008-07-11 2011-03-21 노파르티스 아게 (a) 포스포이노시타이드 3-키나제 억제제 및 (b) ras/raf/mek 경로의 조절제의 조합물
AU2009282574B2 (en) * 2008-08-20 2014-08-21 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR072937A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituida y su uso en el tratamiento de infecciones virales
JP5654990B2 (ja) 2008-08-20 2015-01-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. アゾ置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
JP5674661B2 (ja) 2008-08-20 2015-02-25 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
UY32153A (es) * 2008-09-30 2011-04-29 Exelixis Inc Inhibidores de piridomidinona de pi13ka(alfa) y mtor
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
RS53768B1 (sr) 2010-12-16 2015-06-30 F. Hoffmann-La Roche Ag. Triciklična pi3k inhibitorna jedinjenja i postupci korišćenja
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
JP6058009B2 (ja) 2011-08-31 2017-01-11 ノバルティス アーゲー Pi3k−およびmek−阻害剤の相乗的な組合せ
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
BR112017006113A8 (pt) 2014-10-10 2018-04-24 Pfizer usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
AU2016272881C1 (en) 2015-06-04 2019-10-03 Pfizer Inc. Solid dosage forms of palbociclib
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2019519593A (ja) 2016-07-06 2019-07-11 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンThe Regents Of The University Of Michigan MEK/PI3K及びmTOR/MEK/PI3K生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
US10233188B2 (en) 2016-08-15 2019-03-19 Pfizer Inc. CDK2/4/6 inhibitors
US11241500B2 (en) * 2016-12-14 2022-02-08 Tarveda Therapeutics, Inc. HSP90-targeting conjugates and formulations thereof
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
FI3813946T3 (fi) 2018-06-15 2024-06-25 Janssen Pharmaceutica Nv Rapamysiinianalogeja ja niiden käyttötapoja
WO2020140055A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020140053A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
WO2021113665A1 (en) 2019-12-05 2021-06-10 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN114901664B (zh) * 2020-01-10 2024-07-02 南京再明医药有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
KR20230121758A (ko) 2020-11-18 2023-08-21 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나제 억제제 및 그의 사용 방법
AU2022389984A1 (en) * 2021-11-18 2024-06-13 Traws Pharma, Inc. Methods and compositions for treating cancer
JP2024544632A (ja) 2021-12-03 2024-12-03 デシフェラ・ファーマシューティカルズ,エルエルシー Gcn2及びperkキナーゼ阻害剤としての複素環式化合物
TW202502345A (zh) 2023-06-08 2025-01-16 美商林伯士瓦吉特公司 Wrn抑制劑
US20250206738A1 (en) * 2023-12-21 2025-06-26 Nimbus Wadjet, Inc. Wrn inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009993A1 (en) * 2001-12-11 2004-01-15 Pharmacia Italia S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2005105801A1 (en) * 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
DE69515898T2 (de) 1994-11-14 2000-08-17 Warner-Lambert Co., Morris Plains 6-ARYL-PYRIDO[2,3-d]PYRIMIDINE UND -NAPHTHYRIDINE ZUR HEMMUNG DER DURCH PROTEIN-TYROSIN-KINASE HERVORGERUFENEN ZELLVERMEHRUNG
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6-取代的吡唑并[3,4-d]嘧啶-4-酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
IL150742A0 (en) 2000-01-27 2003-02-12 Warner Lambert Co Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
CA2401368A1 (en) 2000-03-06 2001-09-27 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
MXPA03007623A (es) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
AP1767A (en) 2002-01-22 2007-08-13 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones.
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
BR0309053A (pt) 2002-04-19 2005-02-22 Smithkline Beecham Corp Compostos
AU2003232071A1 (en) 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換6,6−ヘテロ二環式誘導体
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
EP1624900A4 (en) 2003-05-20 2007-05-02 Univ California METHOD OF BINDING AGENTS AT BETA AMYLOID PLAQUE
BRPI0412516A (pt) 2003-07-11 2006-09-19 Warner Lambert Co sal isetionato de um seletivo inibidor cdk4
KR20060097105A (ko) 2003-07-22 2006-09-13 얀센 파마슈티카 엔.브이. C-fms 키나아제 저해제로서의 퀴놀리논 유도체
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CA2553785C (en) 2004-02-14 2011-02-08 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2555724A1 (en) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
JP2007530654A (ja) 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
JP2008501677A (ja) 2004-06-04 2008-01-24 ファイザー・プロダクツ・インク 異常な細胞増殖を治療する方法
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
AU2006302078B2 (en) * 2005-10-07 2012-11-22 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
CN102746298A (zh) * 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
GEP20115306B (2) 2006-09-15 2011-10-10 Pfizer Prod Inc
CA2680796A1 (en) * 2007-03-14 2008-09-18 Exelixis, Inc. Inhibitors of the hedgehog pathway
KR20090130104A (ko) 2007-04-11 2009-12-17 엑셀리시스, 인코포레이티드 암 치료를 위한 pi3k-알파의 억제제로서의 피리도〔2,3­d〕피리미딘­7­온 화합물
UY32153A (es) 2008-09-30 2011-04-29 Exelixis Inc Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009993A1 (en) * 2001-12-11 2004-01-15 Pharmacia Italia S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2005105801A1 (en) * 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents

Also Published As

Publication number Publication date
HK1138589A1 (en) 2010-08-27
GEP20115306B (2) 2011-10-10
TN2009000085A1 (fr) 2010-08-19
KR20090040389A (ko) 2009-04-23
DOP2009000039A (es) 2015-12-15
US20080090801A1 (en) 2008-04-17
PE20080670A1 (es) 2008-06-14
CA2663401C (en) 2011-07-12
SI2074122T1 (sl) 2011-10-28
NZ575167A (en) 2010-10-29
NO342357B1 (no) 2018-05-14
US8633204B2 (en) 2014-01-21
EP2074122B9 (en) 2013-09-11
EA016388B1 (ru) 2012-04-30
AU2007297212B2 (en) 2011-04-14
US8273755B2 (en) 2012-09-25
KR101099926B1 (ko) 2011-12-28
BRPI0716749A2 (pt) 2014-02-18
ES2366489T3 (es) 2011-10-20
NI200900032A (es) 2010-05-14
IL197243A0 (en) 2009-12-24
MX2009002927A (es) 2009-03-31
AP2009004790A0 (en) 2009-04-30
HRP20110621T1 (hr) 2011-09-30
AR062785A1 (es) 2008-12-03
RS20090104A (sr) 2010-06-30
EP2074122B1 (en) 2011-06-29
ES2366489T9 (es) 2013-12-27
MEP8009A (en) 2011-12-20
CN101573358B (zh) 2012-05-30
US7696213B2 (en) 2010-04-13
GT200700077A (es) 2009-08-03
TW200820972A (en) 2008-05-16
DK2074122T5 (da) 2014-03-17
CL2007002682A1 (es) 2008-04-04
CU23783B7 (es) 2012-02-15
AU2007297212B8 (en) 2011-04-28
NO20091141L (no) 2009-03-31
IL197243A (en) 2013-07-31
CY1111911T1 (el) 2015-11-04
TWI334353B (en) 2010-12-11
PT2074122E (pt) 2011-08-24
WO2008032162A8 (en) 2009-03-26
AU2007297212A1 (en) 2008-03-20
JP2010503653A (ja) 2010-02-04
US20120309775A1 (en) 2012-12-06
WO2008032162A1 (en) 2008-03-20
US20100137279A1 (en) 2010-06-03
MA30709B1 (fr) 2009-09-01
ZA200901477B (en) 2010-07-28
HN2007000267A (es) 2011-02-25
DK2074122T3 (da) 2011-08-15
BRPI0716749B8 (pt) 2021-05-25
MY146420A (en) 2012-08-15
CA2663401A1 (en) 2008-03-20
ATE514695T1 (de) 2011-07-15
CR10662A (es) 2009-04-17
CU20090040A7 (es) 2011-07-11
UY30588A1 (es) 2008-05-02
JP4718637B2 (ja) 2011-07-06
HRP20110621T2 (hr) 2013-12-06
RS51927B (sr) 2012-02-29
PL2074122T3 (pl) 2011-10-31
EA200970207A1 (ru) 2009-08-28
CN101573358A (zh) 2009-11-04
EP2074122A1 (en) 2009-07-01
BRPI0716749B1 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
AP2710A (en) Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors
SI1888580T1 (sl) Pirido d pirimidini uporabni kot inhibitorjiHCV in postopki za njihovo pripravo
IL210821A0 (en) Pyrazolopyridine kinase inhibitor compounds, compositions comprising the same and uses thereof
IL198509A0 (en) Azaindole derivatives, compositions containing the same and uses thereof
AP2453A (en) Pyrazolo(3,4-B) pyridine derivatives as phosphodiesterase inhibitors
EP2154965A4 (en) NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS
GB201000648D0 (en) Phosphodiesterase 10 inhibitors
IL206330A0 (en) PYRIDO [2,3-b]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE
IL198250A0 (en) Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b
SI1966202T1 (sl) S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
IL201009A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
IL184717A0 (en) Imidazo (1,2-a)pyridine compounds as vegf-r2 inhibitors
IL201865A0 (en) Rna beta-catenin antagonist compounds, compositions comprising the same and uses thereof
ZA201005338B (en) Pyrrolo[2,3-d]pyridines and use thereof as tyrosine kinase inhibitors
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
SI1697356T1 (sl) Pirido(2,3-d)pirimidin-2,4-diamini kot zaviralci PDE 2
IL207452A0 (en) Pyrrolo pyrimidine derivatives, compositions comprising the same and uses thereof
IL202038A0 (en) Rna antagonist compounds, compositions comprising the same and uses thereof
IL201209A0 (en) Pyrido [2, 3 - d] pyrimidin - 7 - one compounds as inhibitors of pi3k - alpha for the treatment of cancer
EP2061470A4 (en) HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
ZA200904440B (en) 6-Benzyl-2,3,4,7-Tetrahydro-indolo [2,3-C] quinoline compounds useful as PDE5 inhibitors
IL190456A0 (en) Pyrazolo[4,3-d]pirimidin-5-yl)derivative used as pde5 inhibitors
ZA200803658B (en) 2-amino-7,8-dihydro-6H-pyrido[4,3-d] pyrimidin-5-ones
EP1713793A4 (en) PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS